Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies.
暂无分享,去创建一个
D. Olive | P. Viens | J. Pasquier | B. Vialettes | R. Sauvan | D. Maraninchi | A. Stoppa | D. Baume | M. San Marco | M. A. Guillerand